• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Frontier Bio’s Lab-Grown Lungs Offers Hope for Drug Development

by Fred Pennic 10/01/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Frontier Bio Corporation has successfully created complex microscale lung tissue by combining 3D bioprinting with the self-assembling capabilities of stem cells, mirroring the natural organ development process. 

– Frontier Bio’s breakthrough in lab-grown lung tissue signifies a potential turning point in the fight against respiratory diseases and the quest for viable organ transplantation options.

Addressing the Limitations of Animal Testing

Animal testing, a common practice in preclinical drug development, often falls short in accurately representing human biology. This results in high failure rates when new drugs reach human trials. Frontier Bio’s lab-grown human lung tissue provides a more precise model for drug development, potentially increasing the success rate of clinical trials and accelerating the discovery of new treatments.

Harnessing the Power of Stem Cells

Frontier Bio’s lung models are created from a combination of lung cells, including stem cells, mixed with proprietary biomaterials. This mixture is then processed using the company’s bioprinting hardware to create the tissue’s structure. The unique aspect of Frontier Bio’s technology lies in its ability to stimulate natural self-assembly processes, allowing stem cells to differentiate and organize into the intricate microtissue architecture of the distal lung. These lab-grown models even exhibit features like bronchioles, alveolar air sacs, beating cilia, mucus, and surfactant, closely resembling natural lung tissue.

Potential Applications and Impact

The lab-grown lung models offer a valuable platform for studying diseases like lung cancer, pulmonary fibrosis, COPD, and COVID-19, paving the way for new treatments in this significant market. The technology also holds immense promise for creating tissues and organs for transplantation, addressing the critical need for replacement lung tissue for millions of patients worldwide.

“This could fundamentally change the landscape of lung transplants, giving hope to thousands of patients waiting for lifesaving treatment,” added Eric Bennett, CEO of Frontier Bio.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Medical 3D Printing

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |